Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs!
Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation.
▲ notice of approval from the State Drug Administration
Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents.
▲ for medical professionals only
Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad.
As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.
In recent years, the state has vigorously supported and promoted the development of Chinese medicine, put the development of Chinese medicine in a prominent position, made many decisions and deployments, and issued supporting policies for the Chinese medicine science and technology industry. "Guiding Opinions on the Integrated Development of Chinese Medicine Health Services and the Internet" and the "Traditional Chinese Medicine Law" guide the development of the Chinese medicine industry to 2020. The "Administrative Measures for Drug Registration" and "Registration Classification and Application Information Requirements for Chinese Medicines" put forward new requirements for the research and development of new Chinese medicines. All have pointed out the direction for the inheritance and innovation of traditional Chinese medicine, and promoted "the revitalization and development of traditional Chinese medicine usher in a great opportunity for the right time, the right place, and the harmony of people."
In addition, as the aging population increases, people’s health awareness of prevention is better than cure, prevention before disease and prevention of changes in existing diseases. Traditional Chinese medicine with the unique advantages of "preventing diseases" will usher in a good opportunity for development, especially in 2020. The indispensable and important role of Chinese medicine in the prevention and treatment of major diseases demonstrated in the fight against the new crown epidemic has brought new development opportunities for the research and development of new Chinese medicines, and also ushered in opportunities for the revitalization of the development of Chinese medicine and the international development.
In fact, discovering the treasures of the motherland’s medicine, inheriting the essence of innovative Chinese medicine, promoting the R&D and industrial development of Chinese medicine with technological innovation, and developing “effective and high-quality” new Chinese medicines. Pharmaceutical companies regard it as an important mission to achieve their own innovation and upgrade, enhance core competitiveness, and revitalize the development of traditional Chinese medicine.
On September 18, 2021, the "2021 High-Quality Development Conference of the Big Health Industry and the Sixth China Pharmaceutical Research and Development Innovation Summit (PDI)" released the "2021 China TCM R&D Strength Ranking List TOP50" (hereinafter referred to as the "Chinese Medicine List"" ), 50 leading Chinese medicine innovation frontiers.